Vertex Pharmaceuticals (NASDAQ: VRTX) and Mirum Pharmaceuticals (NASDAQ: MIRM) are two biotech stocks that share the same ...

Inside the deadly disease confounding medicine, researchers piecing together clues and the breakthrough that meant survival ...

NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2026 of $0.235 per Class A ...

Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2026 financial results on Wednesday, May 6, 2026 before the U.S. financial markets open. The company will host a ...

Vertex Pharmaceuticals is set to report its first-quarter results next month, and analysts are expecting high single-digit ...

Comedian and "Bob's Burgers" voice actor Eugene Mirman is recovering after being involved in a flaming car crash. ( TMZ) ...

-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the ...

The agency has expanded the use of Alyftrek and Trikafta for treating patients with any genetic variant that results in production of CFTR proteins.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK ® (vanzacaftor ...

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States -With this expansion, any ...

The expanded approval was based on clinical and/or in vitro data demonstrating responsiveness across 564 variants for Alyftrek and 521 variants for Trikafta. The label expansions were granted based on ...

Sign up for the Concord Monitor’s morning newsletter for essential news each day, and our contests and promotions list for special offers and giveaways. In your ...